Skip to main content

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin

Buy Article:

$43.00 plus tax (Refund Policy)

Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: lipid; metabolic syndrome; thiazolidinedione; type 2 diabetes

Document Type: Research Article

Affiliations: ‘G. Descovich’ Atherosclerosis Study Center, ‘D. Campanacci’ Clinical Medicine and Applied Biotechnology Department, University of Bologna, Bologna, Italy

Publication date: 2007-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more